Teva Pharmaceutical Reports a Step Back in 2019
Teva Pharmaceutical Industries (NYSE: TEVA) reported its results from the end of 2019 on Wednesday, and the big story was the headwinds it faced. Generic competition for Copaxone, declining generic drug prices, and a big debt load continued to pester the giant drugmaker, but it looks like all three of those issues are receding.
In 2019, total revenue declined 8% to $16.9 billion, but rising sales of some newer drugs more than offset the falling sales of Copaxone during the last three months of the year.
Image source: Getty Images.
Source Fool.com
